Modality
Cell Therapy
MOA
Menini
Target
Tau
Pathway
Tau
PsoriasisCKDLGS
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ May 2025
Phase 1Current
NCT03117838
853 pts·Psoriasis
2022-12→2025-05·Recruiting
853 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-1910mo agoPh2 Data· Psoriasis
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2025-05-19 · 10mo ago
Psoriasis
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03117838 | Phase 1/2 | Psoriasis | Recruiting | 853 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| TER-5062 | Terns | Phase 2/3 | Tau | |
| TXG-6755 | 10x Genomics | Approved | CD123 | |
| Zoricapivasertib | CSL Limited | Phase 2 | HER2 |